Optimizerx Corp (OPRX) Stock Price, Quote & News

Company Profile

OptimizeRx Corporation operates as a digital healthcare technology company. The company offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, HUB awa...

Industry: Health Information Services

Sector: Healthcare

Phone: 248-651-6568

Website: www.optimizerx.com

Address:

260 Charles Street, Suite 302, Waltham, United States

Eastern_Edge Jul. 29 at 5:10 PM

$OPRX Bears completely silent after year end and Q1 earnings. Sad bears absolutely obliterated into the shadow realm LMAO

0 · Reply

NVDAMillionaire Jul. 28 at 11:08 PM

$OPRX Excellent article that nails exactly where OPRX stands right now. So if you want to update your OPRX knowledge or get acquainted with OPRX, this is a must read. https://beyondspx.com/article/optimizerx-leveraging-integrated-tech-and-data-for-profitable-growth-nasdaq-oprx

0 · Reply

ZacksResearch Jul. 25 at 4:40 PM

$OPRX — Is this digital health player the real deal? 🚀 OptimizeRx delivered 11% year-over-year revenue growth and a shift to a subscription model in Q1 2025, with over 5% of projected annual revenues already converted to subscriptions. Despite risks like macro constraints and regulatory shifts, a Zacks Rank #1 suggests strong buy potential. See what makes the investment case strong for OptimizeRx 👉 https://www.zacks.com/stock/news/2616875/oprx-delivers-solid-q1-earnings-but-can-it-sustain-the-momentum?cid=sm-stocktwits-2-2616875-body-3835&ADID=SYND_STOCKTWITS_TWEET_2_2616875_BODY_3835

0 · Reply

ZacksResearch Jul. 25 at 12:29 PM

$OPRX delivers solid Q1 — but can it keep up the pace? 11% revenue growth and improved EBITDA show strength, but long-term upside depends on scaling subscriptions and margin mix improvements. Full momentum breakdown here 👉 https://www.zacks.com/stock/news/2616875/oprx-delivers-solid-q1-earnings-but-can-it-sustain-the-momentum?cid=sm-stocktwits-2-2616875-teaser-3818&ADID=SYND_STOCKTWITS_TWEET_2_2616875_TEASER_3818

0 · Reply

WOLFSTREET Jul. 25 at 9:04 AM

$OPRX is on a CC LIST, play this horse until it runs out, and it has a ways to go, then move your winnings to $GDRX , the sleeping pills should have worn off by then, but otherwise you can just check back with CC for a 60 second update. I promise its quick, I just did both in less than 2 minutes.

0 · Reply

WOLFSTREET Jul. 25 at 9:00 AM

Only reason $OPRX is beating $GDRX on the track is because OPRX has been chosen by the market to run, while market has GDRX on sleeping pills. Things will flip when pills wear off.

0 · Reply

tijsd Jul. 23 at 2:27 PM

$PAYS if your bullish on pays, check $OPRX

0 · Reply

ZacksResearch Jul. 18 at 1:28 PM

$OPRX up 187.9% YTD — still room to run? 🚀 💡 11% year-over-year revenue growth and a 25% script lift highlight its strategic value. 🔍 With over 80% of 2025 revenues already contracted, the shift to subscription-based models offers margin stability. Discover why OPRX's transformation might be just getting started 👉 https://www.zacks.com/stock/news/2591316/can-oprxs-patient-engagement-tools-win-amid-fierce-competition?cid=sm-stocktwits-2-2591316-body-2533&ADID=SYND_STOCKTWITS_TWEET_2_2591316_BODY_2533

0 · Reply

ZacksResearch Jul. 18 at 11:50 AM

Can $OPRX break through the noise in digital health? It’s leaning on EHR-linked messaging and geo-targeting to differentiate — but scaling in a fiercely competitive space is the real test. Full breakdown here 👉 https://www.zacks.com/stock/news/2591316/can-oprxs-patient-engagement-tools-win-amid-fierce-competition?cid=sm-stocktwits-2-2591316-teaser-2480&ADID=SYND_STOCKTWITS_TWEET_2_2591316_TEASER_2480

0 · Reply

Doozio Jul. 17 at 2:20 AM

$OPRA $OPRX obviously. 🐒🍌🧠⏰♾️

0 · Reply

OptimizeRx: Stock Could Rise As Profitability Is Achieved

Jul 17, 2025, 7:30 AM EDT - 13 days ago

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET

Jun 24, 2025, 7:30 AM EDT - 5 weeks ago

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors

Jun 18, 2025, 3:00 AM EDT - 6 weeks ago

Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions

May 16, 2025, 7:30 AM EDT - 2 months ago

OptimizeRx to Participate in Upcoming Investor Conferences

May 12, 2025, 9:56 PM EDT - 2 months ago

OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 2 months ago

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

May 1, 2025, 4:05 PM EDT - 3 months ago

OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report

Apr 23, 2025, 7:30 AM EDT - 3 months ago

OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

Apr 18, 2025, 4:15 PM EDT - 3 months ago

OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

Mar 12, 2025, 11:56 AM EDT - 5 months ago

OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million

Mar 12, 2025, 11:04 AM EDT - 5 months ago

OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:30 AM EDT - 5 months ago

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 7:30 AM EDT - 5 months ago

OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

Mar 10, 2025, 7:30 AM EDT - 5 months ago

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

Feb 27, 2025, 7:30 AM EST - 5 months ago

OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET

Dec 23, 2024, 8:45 AM EST - 7 months ago

OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

Nov 13, 2024, 10:58 PM EST - 9 months ago

OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:30 AM EDT - 9 months ago

OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET

Sep 10, 2024, 7:30 AM EDT - 11 months ago

OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value

Sep 9, 2024, 12:00 PM EDT - 11 months ago

OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences

Aug 8, 2024, 8:06 PM EDT - 1 year ago

OptimizeRx Corporation (OPRX) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET

Jul 23, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation

Jul 15, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients

Jun 20, 2024, 7:30 AM EDT - 1 year ago

New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations

May 14, 2024, 11:21 PM EDT - 1 year ago

OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:01 PM EDT - 1 year ago

OptimizeRx Reports First Quarter 2024 Financial Results

Apr 26, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET

Apr 18, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report

Apr 16, 2024, 7:00 AM EDT - 1 year ago

OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results

Apr 11, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row

Mar 28, 2024, 11:20 AM EDT - 1 year ago

OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 7:30 AM EDT - 1 year ago

OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET

Mar 11, 2024, 4:30 PM EDT - 1 year ago

OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023

Mar 4, 2024, 3:51 PM EST - 1 year ago

OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach Effort

Jan 25, 2024, 7:30 AM EST - 1 year ago

OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

Jan 9, 2024, 7:30 AM EST - 1 year ago

OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update

Dec 18, 2023, 7:30 AM EST - 1 year ago

OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco

Nov 6, 2023, 11:48 AM EST - 1 year ago

OptimizeRx Corporation (OPRX) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 7:00 AM EST - 1 year ago

OptimizeRx Reports Third Quarter 2023 Financial Results

Oct 25, 2023, 7:30 AM EDT - 1 year ago

OptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ET

Oct 12, 2023, 7:00 AM EDT - 1 year ago

OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers

Aug 24, 2023, 8:00 AM EDT - 2 years ago

OptimizeRx Expands AI Powered Omnichannel Platform

Aug 14, 2023, 6:54 PM EDT - 2 years ago

OptimizeRx Corporation (OPRX) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:01 PM EDT - 2 years ago

OptimizeRx Reports Second Quarter 2023 Financial Results

Jul 31, 2023, 8:01 AM EDT - 2 years ago

OptimizeRx Sets Second Quarter 2023 Conference Call for August 14, 2023 at 4:30 p.m. ET

Jul 21, 2023, 1:47 PM EDT - 2 years ago

OptimizeRx Aims For Growth After Swoon

May 24, 2023, 7:30 AM EDT - 2 years ago

OptimizeRx's CEO Provides 2023 Midyear Strategic Update

May 18, 2023, 8:01 AM EDT - 2 years ago

OptimizeRx's Karina Castagna Named One of the 2023 PM360 ELITE 100

Eastern_Edge Jul. 29 at 5:10 PM

$OPRX Bears completely silent after year end and Q1 earnings. Sad bears absolutely obliterated into the shadow realm LMAO

0 · Reply

NVDAMillionaire Jul. 28 at 11:08 PM

0 · Reply

ZacksResearch Jul. 25 at 4:40 PM

0 · Reply

ZacksResearch Jul. 25 at 12:29 PM

0 · Reply

WOLFSTREET Jul. 25 at 9:04 AM

0 · Reply

WOLFSTREET Jul. 25 at 9:00 AM

Only reason $OPRX is beating $GDRX on the track is because OPRX has been chosen by the market to run, while market has GDRX on sleeping pills. Things will flip when pills wear off.

0 · Reply

tijsd Jul. 23 at 2:27 PM

$PAYS if your bullish on pays, check $OPRX

0 · Reply

ZacksResearch Jul. 18 at 1:28 PM

0 · Reply

ZacksResearch Jul. 18 at 11:50 AM

0 · Reply

Doozio Jul. 17 at 2:20 AM

$OPRA $OPRX obviously. 🐒🍌🧠⏰♾️

0 · Reply

ZacksResearch Jul. 16 at 1:39 PM

$OPRX or $GDRX: Which digital health play has more upside? 🤔 📈 OPRX surged 166.8% YTD with momentum in digital pharma engagement and subscription revenue contributing to its growth. 💰 GDRX up 2.1%, leveraging brand strength and expanding retail partnerships. Discover why OPRX might be the better buy with its Zacks Rank #1 👉 https://www.zacks.com/stock/news/2585294/oprx-vs-gdrx-which-health-tech-stock-has-stronger-revenue-momentum?cid=sm-stocktwits-2-2585294-body-2008&ADID=SYND_STOCKTWITS_TWEET_2_2585294_BODY_2008

0 · Reply

ZacksResearch Jul. 16 at 12:45 PM

$OPRX vs. $GDRX — which health tech name is really delivering? OPRX is riding high on rising subscription revenue and strong pharma demand, while GDRX is dragging from slower consumer growth. Full momentum breakdown here 👉 https://www.zacks.com/stock/news/2585294/oprx-vs-gdrx-which-health-tech-stock-has-stronger-revenue-momentum?cid=sm-stocktwits-2-2585294-teaser-1970&ADID=SYND_STOCKTWITS_TWEET_2_2585294_TEASER_1970

0 · Reply

ZacksResearch Jul. 11 at 4:55 PM

$OPRX surges 173.3% YTD — is this just the beginning? 🚀 🔥 First-quarter revenue up 11% YoY; Adjusted EBITDA hits $1.5M in Q1 📈 Full-year revenue guidance raised to $101-$106M 📊 Forward P/S of 2.22X vs. industry’s 8.86X — undervalued gem? Discover the full potential of OPRX’s strategic evolution here 👉 https://www.zacks.com/stock/news/2573186/optimizerx-bets-on-ai-and-workflow-integration-will-this-pay-off?cid=sm-stocktwits-2-2573186-body-1319&ADID=SYND_STOCKTWITS_TWEET_2_2573186_BODY_1319

0 · Reply

ZacksResearch Jul. 11 at 12:40 PM

$OPRX is going all-in on AI and subscriptions — smart pivot or risky gamble? They're leaning hard into platform integration, but margin pressure and retention risks could bite if execution slips. Full breakdown on the platform shift 👉 https://www.zacks.com/stock/news/2573186/optimizerx-bets-on-ai-and-workflow-integration-will-this-pay-off?cid=sm-stocktwits-0-2573186-teaser-1283&ADID=SYND_STOCKTWITS_TWEET_0_2573186_TEASER_1283

0 · Reply

ZacksResearch Jul. 3 at 1:43 PM

$OPRX surges 69.3% in 3 months — what's driving this explosive growth? 🚀 📈 Revenue up 11% YoY with strong cash flow 🔄 Transition to subscription model gaining traction 📊 Raised FY guidance with more than 25% YoY increase in committed contracted revenue, now exceeding $70 million Discover the full growth story here 👉 https://www.zacks.com/commentary/2561912/oprx-shares-rise-693-in-3-months-time-to-bet-on-the-stock?cid=sm-stocktwits-2-2561912-body-706&ADID=SYND_STOCKTWITS_TWEET_2_2561912_BODY_706

0 · Reply

JarvisFlow Jun. 9 at 5:45 PM

Stifel updates rating for OptimizeRx ( $OPRX ) to Buy, target set at 12.5 → 16.

0 · Reply

Doozio Jun. 6 at 11:04 PM

$OPRA and all da 🐑 been SPOT so scrabble bag it $OPRX during 🐒🍌🧠⏰♾️ as “allegedly” becomes obviously!

0 · Reply

Gergely_Blasko Jun. 6 at 1:58 PM

$OPRX it should pullback to skyrocket. I am bearish short therm (1-2 month).

0 · Reply

kgnfdeagle Jun. 5 at 3:28 PM

$OPRX Added to Homerun portfolio by Brian Bolan at Zacks -- bought 200x at $15.00.

2 · Reply

Maissessap May. 14 at 9:10 AM

$OPRX https://www.tipranks.com/news/the-fly/optimizerx-price-target-raised-to-22-from-16-at-roth-capital

0 · Reply

om8144 May. 13 at 10:27 PM

$OPRX https://www.tipranks.com/news/the-fly/optimizerx-price-target-raised-to-18-from-13-at-b-riley

0 · Reply

JarvisFlow May. 13 at 4:27 PM

Stifel has updated their rating for OptimizeRx ( $OPRX ) to Buy with a price target of 12.5.

0 · Reply

Market Cap	255.23M
Revenue (ttm)	92.13M
Net Income (ttm)	-18.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	119.58
Profit Margin	-20.25%
Debt to Equity Ratio	0.28

Volume	128,638
Avg Vol	272,756
Day's Range	N/A - N/A
Shares Out	18.50M
Stochastic %K	8%
Beta	1.34
Analysts	Strong Sell
Price Target	$15.33